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Replenishing the lost or dysfunctional insulin-producing b cell mass in diabetic patients could slow down or
reverse disease progression. Kondegowda et al. (2015) now show that osteoprotegerin and denosumab, in-
hibitors of the receptor activator of the NF-kB Ligand (RANKL) pathway and osteoclast activation, stimulate
human b cell proliferation and therefore possess therapeutic potential.Type 1 and type 2 diabetes (T1D and T2D)
result from autoimmune destruction or
loss of functional b cell mass, respec-
tively. Daily insulin injections or current
pharmacological treatment do not fully
substitute for b cell loss to prevent uncon-
trolled hyperglycemia and the devastating
secondary complications associated with
both forms of diabetes. The Joslin
Medalist Study demonstrated that even
after 50 years of insulin-dependent dia-
betes, b cells persist and are functional
(Keenan et al., 2010). Hence, strategies
that trigger endogenous b cell replication
or regeneration have great therapeutic
value.
Despite the slow turnover of b cells, b
cell mass can be expanded upon meta-
bolic demand during pregnancy by the
action of lactogenic hormones (Rieck
and Kaestner, 2010). Osteoprotegerin
(OPG) is upregulated in pregnant mice
(Rieck et al., 2009), a finding confirmed
in the study of Kondegowda et al. pub-
lished in Cell Metabolism. Additionally,
OPG was upregulated in other mouse
models associated with increased b cell
expansion, pointing at OPG as universal
mediator of b cell proliferation (Rieck
et al., 2009). OPG acts as soluble decoy
receptor and binds to RANKL and TNF-related apoptosis-inducing ligand (TRAIL)
receptors RANK and death receptor (DR),
respectively, to block their binding (Walsh
and Choi, 2014) (Figure 1). The FDA-
approved drug and humanized mono-
clonal antibody denosumab (DMB) binds
to human RANKL and inhibits RANK re-
ceptor interaction similarly to OPG. Inhibi-
tion of RANK receptor blocks osteoclast
differentiation and promotes bone forma-
tion for osteoporosis therapy (Miller,
2009). Kondegowda et al. show that
OPG and DMB stimulate human b cell
proliferation, raising the possibility that
DMB might be repurposed for b cell
regeneration.
Kondegowda et al. showed OPG upre-
gulation in pancreatic islets of transgenic
mice overexpressing placental lactogen
in b cells compared to normal mice.
They successively identified OPG as
pivotal mediator of lactogen-driven b cell
proliferation. Long-term OPG treatment
caused significant increase in b cell prolif-
eration and mass in young mice, and
induced b cell proliferation in old mice.
OPG injections rescued streptozotocin-
induced b cell ablation, resulting in
reduced diabetes incidence. OPG also
triggered elevated b cell replication in hu-
man islet cells without causing dedifferen-tiation, as measured by PCR analysis
of genes relevant to b cell function.
Glycogen synthase kinase-3 (GSK3b)
and CREB, two factors involved in b cell
proliferation (Dalle et al., 2011; Wang
et al., 2015), were regulated upon OPG
stimulation in rodent and in human islets.
A competition assay in human islet cells
proved that OPG interferes with RANKL/
RANK interaction, thus repressing its
downstream signaling. Thus, RANK sig-
naling puts a brake on b cell proliferation,
which was confirmed in vitro in islets
from the RANK lox animals. Finally, hu-
man islets transplanted under the kidney
capsule of euglycemic immunodeficient
mice exhibited increase b cell proliferation
upon a single injection of DMB, indicating
that the drug acts as a b cell proliferative
trigger in a humanized mouse model.
These pre-clinical results provide
important new clues on lactogenic hor-
mone and RANK signaling in human b
cell proliferation and hold promise for
future clinical use. However, before this
can be achieved we need to understand
how these signaling pathways mechanis-
tically act together to enhance b cell
proliferation. The lactogenic hormones
prolactin (PRL) and placental lactogen
(PL) are elevated during pregnancy
Figure 1. OPG and DMB Induce b Cell Proliferation by Inhibiting RANK/RANKL Pathway
and Modulating GSK3b and CREB
b cell proliferation is enhanced during pregnancy by lactogen signaling via JAK2/STAT5A/B. A novel
transcriptional target of lactogen signaling in b cells is OPG. OPG and its partial functional equivalent
DMB bind RANKL and inhibit RANKL/RANK interaction, thus suppressing downstream signaling. This
results in the phosphorylation of GSK3b and CREB, which in turn might trigger proliferation via activation
of cyclins and CDKs.
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STAT5A/B signaling (Wang et al., 2015)
(Figure 1). However, how prolactin recep-
tor signaling transcriptionally activates
OPG expression in b cells still remains un-
clear and deserves further investigation.
Another open question concerns the
way RANK signaling regulates b cell pro-
liferation. The authors suggest that the
CREB and GSK3b mediate the effect of
OPG, but the intermediate partners in
this signaling cascade are still unknown.
It is known that RANK receptor activates
several signaling cascades that may
phosphorylate and inhibit GSK3b and
promote translocation and activation of
CREB in other cell types (Walsh and
Choi, 2014). How these pathways are
modulated in b cells is unclear. Moreover,
it is not clear whether GSK3b and CREB
act independently to increase OPG-medi-
ated proliferation or interact with each
other. And finally, what are the down-
stream targets of GSK3b and CREB? On
one hand, it is known that GSK3b phos-
phorylation results in activation of b-cate-
nin, which in turn modulates target genes
such as cyclins and cyclin-dependent
kinases (Figure 1) in b cells (Rulifson
et al., 2007). On the other hand, CREB
modulates transcription of insulin andcyclins in response to glucose and incre-
tin hormones (Dalle et al., 2011) (Figure 1).
Further investigation is warranted to
determine whether activation of these
specific targets orchestrates the prolifera-
tive effects of OPG in b cells.
The importance of the RANK pathway
was highlighted in a prospective popula-
tion-based study that showed that
high serum concentration of soluble
RANKLwas an independent risk predictor
for T2D. In addition, circulating OPG
emerged with or after T2D and was unre-
lated to T2D risk. Moreover, OPG treat-
ment of insulin-resistant ob/ob mice
caused enhanced insulin sensitivity, sug-
gesting another positive effect of OPG
(Kiechl et al., 2013). Given that DMB is
an FDA-approved drug with tolerable
side effects, it is worth investigating its
effect on diabetic patients and the possi-
bility of repurposing the drug. However,
some limitations exist. Currently, there
are no approved methods to determine b
cell mass in humans. Moreover, it will
also be necessary to address the question
whether the 2- to 3-fold increase in b cell
proliferation by OPG is sufficient to
compensate for a deregulated glucose
homeostasis in diabetic patients; inter-
fering with mitogenic signaling of humanCell Metabolb cells is difficult, and treatment of b cells
with a GSK3b inhibitor only enhanced b
cell proliferation from 0.17% to 0.71%
(Wang et al., 2015).
Post hoc analysis from trials investi-
gating the effect of DMB and placebo on
postmenopausal women did not find sig-
nificant differences in glucose homeosta-
sis and diabetes incidence (Schwartz
et al., 2013). However, these trials were
not designed for this purpose. Long-
term randomized placebo-controlled clin-
ical trials with diabetic patients are
needed to evaluate the efficacy of OPG
or DMB to slow down the progression of
diabetes or, even better, to prevent the
development of this devastating disease.
The findings by Kondegowda et al.
highlight a novel promising approach to
stimulate b cell expansion that may pave
the way for a more efficacious and less
cumbersome therapeutic intervention in
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